Page 1 of 3
HPTA Restart: Meta-Analysis of PCT Protocols
Posted: Thu Sep 26, 2024 10:53 am
by MedellinMuscle
Meta-analysis shows that HCG during a cycle preserves Leydig cell sensitivity. Why do so many still wait until the cycle is over to start recovery?
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 11:13 am
by MedellinMuscle
The data on RAD-140 is particularly interesting. Its Ki value suggests an affinity almost rivaling dihydrotestosterone.
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 12:13 pm
by Peterdyday
True, but affinity doesn't always equal intrinsic activity. We need to look at the co-regulator recruitment post-binding.
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 1:33 pm
by SlavPower
I agree with @DataDriven_Lift. If the SARM binds but doesn't recruit the right co-activators in bone tissue, the selective part of SARM is lost.
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 2:53 pm
by CoachIronwell
Has anyone seen the latest 2025 paper on LGD-3033? The binding curve is significantly steeper than the older 4033 variant.
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 3:53 pm
by Herbertysnilm
From a clinical standpoint, the higher the affinity, the more suppression we generally see at the HPTA level. There is no free lunch.
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 4:53 pm
by MedellinMuscle
@CommonSenseMD exactly. People forget these are still androgens. Competitive binding at the hypothalamus is inevitable.
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 7:47 pm
by SlavPower
Is there any evidence of S3 selective binding in prostate tissue for the newer compounds?
Re: SARM Binding Affinity
Posted: Thu Sep 26, 2024 11:23 pm
by Peterdyday
Minimal. Most "selectivity" in marketing is just lower overall potency masked as tissue-specific action.
Re: SARM Binding Affinity
Posted: Fri Sep 27, 2024 1:53 am
by CoachIronwell
We should also discuss the dissociation rate. How long the molecule stays bound to the AR determines the genomic response.